Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AAV-shRNA targeting Msh3
- Development stage
- Preclinical
- Lead developer
- Brigham and Women's Hospital
- Modality
- Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
AAV-shRNA targeting Msh3 is an experimental gene therapy designed to treat Huntington's Disease (HD) by inhibiting somatic repeat expansion. HD is caused by a CAG trinucleotide repeat expansion in the HTT gene, and somatic expansion of these repeats is driven by the DNA mismatch repair pathway, specifically the MSH3 protein. This therapy utilizes adeno-associated virus (AAV) vectors—including scAAV9 and AAV-CPP16 capsids—to deliver short hairpin RNA (shRNA) that knocks down Msh3 expression in the striatum. To overcome the blood-brain barrier (BBB), the therapy is being investigated in combination with focused ultrasound (FUS) and microbubbles for non-invasive delivery.
- Other names
- AAV-shRNA-Msh3AAV-shRNA-Msh-3AAV-shRNA-Msh 3scAAV9-shRNA-Msh3scAAV-9-shRNA-Msh3scAAV 9-shRNA-Msh3AAV-CPP16-shRNA-Msh3AAV-CPP-16-shRNA-Msh3AAV-CPP 16-shRNA-Msh3
02
Targets
Beyond the preview
Go deeper on AAV-shRNA targeting Msh3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AAV-shRNA targeting Msh3.